| 000 | 01421 a2200397 4500 | ||
|---|---|---|---|
| 005 | 20250518092705.0 | ||
| 264 | 0 | _c20200506 | |
| 008 | 202005s 0 0 fre d | ||
| 022 | _a1769-6917 | ||
| 024 | 7 |
_a10.1016/j.bulcan.2020.01.012 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _adu Payrat, Juliette Abeillon | |
| 245 | 0 | 0 |
_a[Checkpoint inhibitors-induced hypophysitis]. _h[electronic resource] |
| 260 |
_bBulletin du cancer _cApr 2020 |
||
| 300 |
_a490-498 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAdrenal Cortex Hormones _xtherapeutic use |
| 650 | 0 | 4 |
_aB7-H1 Antigen _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aCTLA-4 Antigen _xantagonists & inhibitors |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHyponatremia _xetiology |
| 650 | 0 | 4 |
_aHypophysitis _xdiagnostic imaging |
| 650 | 0 | 4 |
_aImmunotherapy _xadverse effects |
| 650 | 0 | 4 | _aMagnetic Resonance Imaging |
| 650 | 0 | 4 |
_aNeoplasms _xtherapy |
| 650 | 0 | 4 |
_aProgrammed Cell Death 1 Receptor _xantagonists & inhibitors |
| 650 | 0 | 4 | _aRisk Factors |
| 700 | 1 | _aCugnet-Anceau, Christine | |
| 700 | 1 | _aMaillet, Denis | |
| 700 | 1 | _aLevy, Manon | |
| 700 | 1 | _aRaverot, Gérald | |
| 700 | 1 | _aDisse, Emmanuel | |
| 700 | 1 | _aBorson-Chazot, Françoise | |
| 773 | 0 |
_tBulletin du cancer _gvol. 107 _gno. 4 _gp. 490-498 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.bulcan.2020.01.012 _zAvailable from publisher's website |
| 999 |
_c30769448 _d30769448 |
||